Longer Duration of Drug Elimination and Withdrawal Symptoms in Overweight Patients Undergoing Detoxification for Benzodiazepine Dependence.

Authors

Anna Basińska-Szafrańska

Published in

Alpha psychiatry. Volume 27. Issue 4. Pages 51895. Epub Aug 20, 2026.

Abstract

In patients undergoing detoxification for benzodiazepine (BZD) dependence, withdrawal symptoms frequently persist into the low-concentration phase following drug discontinuation. Prolonged drug elimination may extend the duration of required medical supervision. Because lipophilic BZDs can accumulate in adipose tissue and be released gradually during detoxification, overweight patients may experience delayed elimination. This study quantitatively examined whether BZD elimination and the duration of withdrawal symptoms are prolonged in overweight patients.
From 508 records of concentration-monitored detoxification, a retrospective sample of 290 inpatients matched for diet and physical activity was selected. All patients underwent detoxification according to the SAER protocol (Satiation, Anti-accumulation paradigm, Elimination, and Readaptation). Following (S) satiation with diazepam, further unnecessary (A) accumulation was prevented through aggressive day-by-day dose reductions guided by serum concentration monitoring. Subsequent tapering, leading to effective (E) elimination, was adjusted according to the evolving intensity of withdrawal symptoms, characterized by episodes of peak severity (withdrawal crises) interspersed with periods of relative relief. Completion of (R) readaptation was defined by the cessation of withdrawal symptoms after elimination. The duration of effective elimination, from peak serum concentration to undetectable levels, with particular attention to the post-discontinuation phase, was recorded. Concomitant medications known to influence BZD elimination were identified. Elimination parameters and the timing of clinically significant withdrawal crises were analyzed in relation to patients' body mass index (BMI).
Elimination duration was positively correlated with BMI (ρ = 0.39, p < 0.001). The timing of the strongest and/or the final crises also showed weak but significant positive correlations with BMI in the overall sample (ρ = 0.18 and 0.15, p < 0.01 and < 0.05 cutoff, respectively), and within the identified co-medication subgroups, including the valproate, carbamazepine, and no-modifier groups (ρ = 0.19-0.26, all p < 0.05). These associations accounted for a small proportion of the variance in overall time to withdrawal crisis (R² = 0.02-0.07). Nevertheless, they translated into an additional 8-11 days of necessary monitored care among obese patients. Elimination duration was further prolonged in patients receiving valproate. Extended elimination was not associated with reduced withdrawal symptom severity.
Among patients undergoing detoxification for BZD dependence, higher BMI was associated with prolonged drug elimination and a longer duration of recurring withdrawal crises, without attenuation of symptom severity. Although the observed associations were modest and potentially influenced by confounding factors, they suggest that overweight patients may require extended monitoring during detoxification. Prospective studies are needed to confirm these findings. To reduce the risk of delayed withdrawal crises and maintain treatment within reasonable time frames, minimizing excessive BZD accumulation through laboratory-guided dose adjustment is recommended.

PMID:
42694906
Bibliographic data and abstract were imported from PubMed on 04 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.